Introduction to
FFPE Blocks for Biotech Companies
Research-Grade FFPE Blocks for Biotechnology Innovation
Biotechnology companies developing molecular diagnostics, oncology assays, digital pathology tools and therapeutic platforms require reliable access to representative tumor specimens. FFPE blocks are widely used because they preserve tissue architecture while supporting multiple analytical techniques, including histology, immunohistochemistry, molecular testing and sequencing. Research-grade FFPE collections can help biotech teams evaluate new assays across diverse tumor types, histological subtypes and biomarker categories.
Specimens may be selected according to tumor percentage, stage, grade, molecular profile, treatment status and other protocol requirements. This allows early-stage and growth-stage biotechnology companies to test technologies against clinically relevant materials without building an independent biobank from the beginning. FFPE blocks can support proof-of-concept development, analytical testing, machine-learning model development, biomarker research and retrospective validation studies across multiple oncology indications.
FFPE Tumor Specimens for Assay and Diagnostic Development
Developing a new oncology assay requires access to tumor specimens representing positive, negative and borderline biological states. FFPE tumor blocks can support analytical development of immunohistochemistry assays, FISH probes, PCR-based tests, NGS workflows and other molecular-diagnostic technologies. Biotech companies can define cohorts based on biomarker expression, mutation status, amplification, fusion status, histological subtype or tumor content.
Such structured sample sets can be useful for optimizing sensitivity, specificity, reproducibility and analytical performance before larger clinical validation programs. When available, existing pathology and molecular information can reduce the amount of preliminary screening needed to identify suitable cases. The same FFPE materials may also be used for tissue microarray development, extraction optimization or cross-platform comparison studies. Customized sourcing therefore enables biotech developers to align specimen selection with the precise biological requirements of their technology.
Molecularly Annotated FFPE Samples for Emerging Biotech Platforms
Modern biotechnology platforms increasingly combine pathology, genomics, transcriptomics, proteomics and computational analysis. Molecularly annotated FFPE samples allow developers to evaluate technologies using specimens with known or partially characterized biological features. Annotation may include mutation results, gene-expression information, protein biomarkers, FISH findings, NGS data or clinical variables where available.
These data can be especially useful for companies developing artificial-intelligence models, multi-omics platforms, precision-oncology tools and patient-stratification technologies. Instead of starting with completely uncharacterized tissue, biotech researchers can build targeted validation sets enriched for the biological patterns their technology is designed to detect. Molecularly annotated FFPE specimens may also help developers compare predicted results with existing reference measurements, supporting algorithm optimization, assay benchmarking and hypothesis generation during early product development.
Custom Oncology FFPE Cohorts for Biotech Research Programs
Biotechnology companies frequently work with narrower study populations than conventional academic research programs. A custom FFPE cohort can be assembled according to disease type, histology, biomarker status, molecular alteration, tumor percentage, stage, grade, sample age and available clinical information. This enables biotech teams to focus resources on the samples most likely to answer their development questions.
Customized cohorts can support biomarker discovery, companion diagnostic research, software validation, drug-response studies and analytical performance testing. Depending on availability, cohorts may include matched pathology data, digital slide images, IHC results or molecular information. Such flexibility can be valuable for startups and established biotechnology companies that need scalable access to tissue without maintaining extensive internal biobanking infrastructure. Well-defined FFPE cohorts can shorten research timelines and support more efficient development of next-generation diagnostic and therapeutic technologies.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.